

2Q 2018 Access Meter Report

RE's quarterly report evaluates likely access challenges of near-term launches

Drugs Included in 2Q 2018 Report

Brand (generic)	Indication
Aimovig (ereenumab)	Migraine
Ajovy (fremanezumab)	Migraine
ALIS (amikacin liposome inhalation suspension)	Cystic fibrosis NTM
Biktarvy (bictegravir/emtricitabine/tenofovir)	HIV
binimetinib/encorafenib	Melanoma (BRAF+)
brexanolone	Postpartum depression
Calquence (acalabrutinib)	CLL
Dupixent-asthma (dupilumab)	Eosinophilic asthma
elagolix	Endometriosis
Epidiolex (cannabidiol)	Lennox-Gastaut and Dravet syndrome
fevipiprant	Asthma
Galafold (migalastat)	Fabry's disease
galcanezumab	Migraine
Ilumya (tildrakizumab)	Psoriasis
inotersen	TTR amyloidosis
ivosidenib	AML (R/R, IDH1+)
lanadelumab	Hereditary angioedema
larotrectinib	TRK+ cancers
luspatercept	Chronic anemia
Mavenclad (cladribine)	MS
Olumiant (baricitinib)	RA
ozanimod	MS
Palynziq (pegvaliase-pgpz)	Phenylketonuria
patisiran	TTR amyloidosis
risankizumab	Psoriasis
samidorphan/buprenorphine	Major depressive disorder
selumetinib	Thyroid cancer
Sympazan PharmFilm (clobazam)	Lennox-Gastaut syndrome
Waylivra (volanesorsen)	Familial chylomicronemia syndrome

To learn more about Access Meter, please contact info@realendpoints.com or 973-805-2300